Pulling SEC filings + quote and writing the call…

Celcuity Inc.
Next earnings Aug 12, 2026 (after close) · consensus $-1.13 EPS
Last earnings +8.2% on 2026-05-14
Binary PI3K/mTOR bet on gedatolisib — VIKTORIA-1 cohort 1 readout in hand, well-funded into next catalyst, but pre-revenue and burning ~$153M/yr.
Celcuity is a textbook single-asset clinical-stage biotech: per the 10-K, it 'has not yet commercialized a pharmaceutical product' and since inception in January 2012 has 'had no revenue.' The entire equity value rests on gedatolisib, a pan-class I PI3K plus mTORC1/2 inhibitor licensed from Pfizer in April 2021, now in two Phase 3 trials (VIKTORIA-1 in HR+/HER2- advanced breast cancer, where cohort 1 PIK3CA-WT has 'reported detailed results' and cohort 2 PIK3CA-MT has 'completed enrollment') and Phase 1b/2 CELC-G-201 in mCRPC. Management's pitch — pan-isoform PI3K + mTORC1/2 inhibition avoiding the feedback-loop resistance and the hyperglycemia/rash/diarrhea toxicity that derailed alpelisib (39% Grade 3/4 hyperglycemia, 26% discontinuation in the PIQRAY pivotal) — is mechanistically credible and is the differentiator that justifies the +6.84% reaction today.
Sources: SEC EDGAR (CIK 0001603454, latest 10-Q filed 2026-05-14) · EODHD · analysis by claude-code · as of 6/25/2026, 12:47:09 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$28.4M | -$39.4M | -$66.2M | -$113M | -$172M |
| Net income | -$29.6M | -$40.4M | -$63.8M | -$112M | -$177M |
| Diluted EPS | — | -$2.64 | -$2.69 | -$2.83 | -$3.79 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
New credit facility + replaced prior loan; adds debt obligations alongside other disclosures
Reg FD update/data disclosure; stock reaction suggests positive gedatolisib news
Amendment to prior 8-K, likely correcting vote/officer disclosure details
Annual meeting vote results plus board/officer change disclosed
Q1 2026 10-Q: ongoing operating losses, Phase 3 VIKTORIA trials progressing
Q1 2026 10-Q: ongoing operating losses, Phase 3 VIKTORIA trials progressing
Reg FD / other-events update, likely conference or pipeline disclosure
2026 proxy: director slate, say-on-pay, equity plan items for annual meeting
FY25 10-K: -$177M loss, $166M cash, $138M LT debt, going-concern-adjacent burn
1070 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-06-05 | Murphy Polly A. Director | Award | 1.53K | |
| 2026-06-05 | Dalvey David Director | Award | 1.53K | |
| 2026-06-05 | ROMP CHARLES R Director | Award | 1.53K | |
| 2026-06-05 | NIGON RICHARD Director | Award | 1.53K | |
| 2026-06-05 | Furcht Leo Director | Award | 1.53K | |
| 2026-06-05 | Buller Richard E Director | Award | 1.53K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.